These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 18316282)

  • 1. The implementation of buprenorphine/naloxone in college health practice.
    DeMaria PA; Patkar AA
    J Am Coll Health; 2008; 56(4):391-3. PubMed ID: 18316282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
    Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S
    Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
    Fudala PJ; Bridge TP; Herbert S; Williford WO; Chiang CN; Jones K; Collins J; Raisch D; Casadonte P; Goldsmith RJ; Ling W; Malkerneker U; McNicholas L; Renner J; Stine S; Tusel D;
    N Engl J Med; 2003 Sep; 349(10):949-58. PubMed ID: 12954743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
    Curcio F; Franco T; Topa M; Baldassarre C;
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid drugs in maintenance and detoxification treatment of opiate addiction; addition of buprenorphine and buprenorphine combination to list of approved opioid treatment medications. Interim final rule.
    Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services
    Fed Regist; 2003 May; 68(99):27937-9. PubMed ID: 12762334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine in the treatment of opiate dependence.
    Wesson DR; Smith DE
    J Psychoactive Drugs; 2010 Jun; 42(2):161-75. PubMed ID: 20648912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case series of buprenorphine/naloxone treatment in a primary care practice.
    Doolittle B; Becker W
    Subst Abus; 2011 Oct; 32(4):262-5. PubMed ID: 22014257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
    Strain EC; Walsh SL; Bigelow GE
    Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Office-based buprenorphine treatment for opioid-dependent patients.
    McCance-Katz EF
    Harv Rev Psychiatry; 2004; 12(6):321-38. PubMed ID: 15764468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine for office-based treatment of patients with opioid addiction.
    Manlandro JJ
    J Am Osteopath Assoc; 2005 Jun; 105(6 Suppl 3):S8-13. PubMed ID: 16118361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine and naloxone interactions in methadone maintenance patients.
    Mendelson J; Jones RT; Welm S; Brown J; Batki SL
    Biol Psychiatry; 1997 Jun; 41(11):1095-101. PubMed ID: 9146820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
    Mammen K; Bell J
    Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Office-based practice and opioid-use disorders.
    Clark HW
    N Engl J Med; 2003 Sep; 349(10):928-30. PubMed ID: 12954740
    [No Abstract]   [Full Text] [Related]  

  • 14. Bupreorphine:a new pharmacotherapy for opioid addictions treatment.
    Stock C; Shum JH
    J Pain Palliat Care Pharmacother; 2004; 18(3):35-54. PubMed ID: 15364630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid Addiction Treatment Using Buprenorphine-Naloxone In A Community-Based Internal Medicine Practice.
    Van Doren BA; Foulks-Rodriguez KA; Yarborough W
    J Okla State Med Assoc; 2015 Jul; 108(7):303-9. PubMed ID: 26390769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs approved for opiate dependence.
    FDA Consum; 2003; 37(1):6. PubMed ID: 12625293
    [No Abstract]   [Full Text] [Related]  

  • 17. Buprenorphine and naloxone interactions in opiate-dependent volunteers.
    Mendelson J; Jones RT; Fernandez I; Welm S; Melby AK; Baggott MJ
    Clin Pharmacol Ther; 1996 Jul; 60(1):105-14. PubMed ID: 8689806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine in the treatment of opiate dependence: its pharmacology and social context of use in the U.S.
    Wesson DR
    J Psychoactive Drugs; 2004 May; Suppl 2():119-28. PubMed ID: 15279124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
    Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine: a primer for emergency physicians.
    Sporer KA
    Ann Emerg Med; 2004 May; 43(5):580-4. PubMed ID: 15111917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.